BENIGN PROSTATIC HYPERPLASIA: A POSSIBILITY TO USE TYPE 5 PHOSPHOESTERASE INHIBITORS

Prostate adenoma is a polygenic disease manifested by enlargement of the prostate gland and impaired urination. Benign prostatic hyperplasia (BPH) is quite common, many researchers say about the inevitability of this condition in men, however, prostate enlargement is not always evident clinically. The majority of patients suffering from BPH have no complaints for a long time. Depending on severity of clinical manifestations, patients may be offered dynamic follow-up, medical therapy or surgical treatment. Analysis of the existing literature has shown a possibility of effective use of Type 5 phosphodiesterase inhibitors (PDE-5) not only in the treatment of erectile dysfunction (ED) but also in the treatment of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia. The only drug of the PDE-5 inhibitors group registered for treatment of LUTS in BPH is tadalafil use of which in equal shares is manifested by reduced severity of moderate and severe symptoms of accumulation and discharge in men with erectile dysfunction and not affected by it